On average, three driver mutations per tumor were identified with the most common gene alterations including TP53 (36.8%), CDKN2A/B (20.2%), CDK4/MDM2 (19.3%), ATRX (13.2%), and RB1 (13.2%).33 Here, CDKN2A is linked to neoplasm.